There were much fewer STEMI patients on beta blockers and aspirin compared to CAD patients (9% vs. 57% and 18% vs. 79%, respectively), and much fewer NSTEMI patients on ACE inhibitors and aspirin compared to CAD patients (8% vs. 50% and 26% vs. 79%, respectively). This evidence concerns the gene ACE and coronary artery disorder.